109 related articles for article (PubMed ID: 31654719)
1. Vav1 mutations: What makes them oncogenic?
Farago M; Yarnitzky T; Shalom B; Katzav S
Cell Signal; 2020 Jan; 65():109438. PubMed ID: 31654719
[TBL] [Abstract][Full Text] [Related]
2. Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes.
Shalom B; Farago M; Pikarsky E; Katzav S
Oncogenesis; 2018 Oct; 7(10):80. PubMed ID: 30297765
[TBL] [Abstract][Full Text] [Related]
3. Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.
Katzav S
Oncotarget; 2015 Oct; 6(30):28731-42. PubMed ID: 26353933
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the Oncogenic Potential of VAV1 in Human Cancer: Lessons from Mouse Models.
Shalom B; Salaymeh Y; Risling M; Katzav S
Cells; 2023 Apr; 12(9):. PubMed ID: 37174676
[TBL] [Abstract][Full Text] [Related]
5. Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies.
Katzav S
Cancer Lett; 2007 Oct; 255(2):241-54. PubMed ID: 17590270
[TBL] [Abstract][Full Text] [Related]
6. Vav1: a hematopoietic signal transduction molecule involved in human malignancies.
Katzav S
Int J Biochem Cell Biol; 2009 Jun; 41(6):1245-8. PubMed ID: 19100858
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity.
Lazer G; Pe'er L; Farago M; Machida K; Mayer BJ; Katzav S
J Biol Chem; 2010 Jul; 285(30):23075-85. PubMed ID: 20457609
[TBL] [Abstract][Full Text] [Related]
8. Mutation of Vav1 adaptor region reveals a new oncogenic activation.
Razanadrakoto L; Cormier F; Laurienté V; Dondi E; Gardano L; Katzav S; Guittat L; Varin-Blank N
Oncotarget; 2015 Feb; 6(4):2524-37. PubMed ID: 25426554
[TBL] [Abstract][Full Text] [Related]
9. The association of Sam68 with Vav1 contributes to tumorigenesis.
Lazer G; Pe'er L; Schapira V; Richard S; Katzav S
Cell Signal; 2007 Dec; 19(12):2479-86. PubMed ID: 17855053
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin is an oncogenic Vav1- but not wild-type Vav1-responsive gene: implications for fibroblast transformation.
Schapira V; Lazer G; Katzav S
Cancer Res; 2006 Jun; 66(12):6183-91. PubMed ID: 16778192
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.
Robles-Valero J; Fernández-Nevado L; Cuadrado M; Lorenzo-Martín LF; Fernández-Pisonero I; Abad A; Redín E; Montuenga L; Martín-Zanca D; Bigas A; Mallo M; Dosil M; Bustelo XR
Mol Oncol; 2022 Oct; 16(19):3533-3553. PubMed ID: 35895495
[TBL] [Abstract][Full Text] [Related]
12. Vav1 GEF activity is required for T cell mediated allograft rejection.
Haubert D; Li J; Saveliev A; Calzascia T; Sutter E; Metzler B; Kaiser D; Tybulewicz VL; Weckbecker G
Transpl Immunol; 2012 Jun; 26(4):212-9. PubMed ID: 22456277
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Vav1 induces Rac-dependent apoptosis via inhibition of Bcl-2 family proteins and collaborates with p53 deficiency to promote hematopoietic progenitor cell proliferation.
Gu Y; Siefring JE; Wang L; Chae HD; Bailey JR; Zheng Y
Oncogene; 2006 Jun; 25(28):3963-72. PubMed ID: 16474842
[TBL] [Abstract][Full Text] [Related]
14. Remedial strategies in structural proteomics: expression, purification, and crystallization of the Vav1/Rac1 complex.
Brooun A; Foster SA; Chrencik JE; Chien EY; Kolatkar AR; Streiff M; Ramage P; Widmer H; Weckbecker G; Kuhn P
Protein Expr Purif; 2007 May; 53(1):51-62. PubMed ID: 17275330
[TBL] [Abstract][Full Text] [Related]
15. Vav1 Promotes B-Cell Lymphoma Development.
Shalom B; Farago M; Salaymeh Y; Sebban S; Pikarsky E; Katzav S
Cells; 2022 Mar; 11(6):. PubMed ID: 35326399
[TBL] [Abstract][Full Text] [Related]
16. The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis.
Lazer G; Idelchuk Y; Schapira V; Pikarsky E; Katzav S
J Pathol; 2009 Sep; 219(1):25-34. PubMed ID: 19533802
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis.
Robles-Valero J; Fernández-Nevado L; Lorenzo-Martín LF; Cuadrado M; Fernández-Pisonero I; Rodríguez-Fdez S; Astorga-Simón EN; Abad A; Caloto R; Bustelo XR
EMBO J; 2021 Nov; 40(22):e108125. PubMed ID: 34617326
[TBL] [Abstract][Full Text] [Related]
18. Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment.
Shalom B; Farago M; Salaymeh Y; Sebban S; Risling M; Pikarsky E; Katzav S
Cell Signal; 2022 Sep; 97():110395. PubMed ID: 35752351
[TBL] [Abstract][Full Text] [Related]
19. The C1 domain of Vav3, a novel potential therapeutic target.
Kelsey JS; Géczy T; Kaler CJ; Blumberg PM
Cell Signal; 2017 Dec; 40():133-142. PubMed ID: 28927664
[TBL] [Abstract][Full Text] [Related]
20. VAV1 mutations contribute to development of T-cell neoplasms in mice.
Fukumoto K; Sakata-Yanagimoto M; Fujisawa M; Sakamoto T; Miyoshi H; Suehara Y; Nguyen TB; Suma S; Yanagimoto S; Shiraishi Y; Chiba K; Bouska A; Kataoka K; Ogawa S; Iqbal J; Ohshima K; Chiba S
Blood; 2020 Dec; 136(26):3018-3032. PubMed ID: 32992343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
